The order in which the FDA will establish clear guidance as to how companies can get these classes of generic biotech/follow on biologics/pick-a-name drugs approved.
An issue that will be quite important in regards to reducing the future cost of health care in the United States and elsewhere.
It will also increase the likelihood that Great Britain and elsewhere will approve public health spending on such drugs.
Market Data 
Markets 
AI
